We provide a general condition for the occurrence of a sudden transition to synchronization in an array of oscillators mutually coupled via the nearest neighbors. At the onset of synchronization a specific constraint must be fulfilled: precisely, the response time of a single system to signals from the adjacent sites must be smaller than the refractory period. We verify this criterion in some models for neuronal dynamics, namely, in excitable systems driven by noise as well as in chaotic oscillators.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/PhysRevE.78.016202 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Nat Med
January 2025
Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), University of Vic - Central University of Catalonia, Barcelona, Spain.
Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC.
View Article and Find Full Text PDFMeridional anisotropy in contrast sensitivity and visual evoked potential in adults with high myopic astigmatism.
Front Neurosci
January 2025
School of Optometry, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China.
Purpose: Astigmatism can lead to meridional amblyopia, an orientation-specific visual deficit. This study investigated the effects of astigmatism on meridional anisotropy in contrast sensitivity (CS) and steady-state visual evoked potential (ssVEP) across a range of spatial frequencies.
Methods: Thirty-two young adults with a best-corrected distance visual acuity of logMAR 0 or better were categorized into two groups: highly astigmatic (HAS, = 16) with spherical-equivalent error (SE) ≥ -6.
The concept of difficult-to-treat disease in rheumatology: where next?
Lancet Rheumatol
January 2025
College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
New pathogenesis-based therapeutics and evidence-based consensus treatment recommendations, often with predefined treatment goals, have remarkably improved outcomes across many chronic diseases. However, a clinically significant subgroup of patients responds poorly to interventions and show a progressive decline in the disease trajectory, which poses an increasing health-care challenge. Difficult-to-treat approaches exist in several areas of medicine and the need for similar definitions has recently also emerged in rheumatology.
View Article and Find Full Text PDFReduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events.
Eur J Cancer
January 2025
Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; German Cancer Consortium (DKTK), Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; Experimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany. Electronic address:
Background: Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity.
Methods: We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations.
A Response to: Letter to the Editor Regarding "Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance".
Rheumatol Ther
January 2025
Pfizer SLU, Madrid, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!